In DCRI’s Gastroenterology (GI) program, clinical-translational and basic science experts come together to seek out bold and innovative treatments for complex digestive disorders and diseases.

This partnership positions Duke University and the DCRI as one of the leading GI and hepatology research centers in the world.

GI Research that Spans the Disease Spectrum

Our GI faculty comprises practicing physicians in Duke’s GI division, one of the leading clinical programs in the U.S. They partner with basic scientists who focus on genetics and genomics, liver injury and repair, endocrinology, metabolism, and the pathophysiologic mechanisms underlying obesity and its complications.

The result of this collaboration is a track record of successful research in drug development and outcomes that spans commercial industries, government entities, and academia. We’ve successfully coordinated more than 60 gastroenterology and hepatology studies with more than 10,000 patients enrolled across 800 global sites.

Andrew Muir

"Duke’s GI division ranks among the leading programs in the country. Our faculty are practicing physicians with first-hand experience treating patients and a broad range of clinical expertise."

— Andrew Muir, MD, MHS
Director, DCRI Gastroenterology

A Comprehensive Offering of GI Research Services and Expertise

Our experienced and consistent Clinical Operations teams expertly manage all aspects of local and multinational GI clinical trials, including:

We also offer specialized capabilities, many of which are unique to the DCRI:

  • Adaptive trial designs
  • Biobanking
  • Implementing genetics- and genomics-based technologies into clinical trial design
  • Real-time HCV RNA Monitoring
  • Outcomes research: economic analysis and quality-of-life assessments

Our Clinical Research Expertise

  • Barrett’s Esophagus
  • Colorectal cancer
  • Drug-induced Liver Injury
  • Esophageal cancer
  • Gastroesophageal reflux disease
  • Gastrointestinal bleeding
  • Hepatitis B
  • Hepatitis C
  • Hepatocellular carcinoma
  • HIV/HCV co-infection
  • Inflammatory bowel disease
  • Irritable bowel syndrome
  • Liver transplantation
  • Noninvasive fibrosis markers
  • Nonalcoholic fatty liver disease (NAFLD/NASH)
  • Pancreatitis
  • Pancreatic cancer
  • Pediatric GI and liver disease
  • Portal hypertension
  • Primary sclerosing cholangitis




Research challenges posed by the era of “big data,” the promise of an optical sensor in colonoscopy and biopsy, and recent changes to colon cancer screening guidelines are covered in this audio interview with Deborah Fisher, MD. Click the play button above to listen.


Pills in the shape of a liver


Established in 2003, the Drug-Induced Livery Injury Network (DILIN) collects and analyzes cases of liver injury to help better understand their source. The network’s latest award allows more study on the impact of genetics, specific drugs, and supplements.

David Leiman, MD, MSHP


David Leiman, MD, MSHP, was inducted into the third class of the American Gastroenterological Association's Future Leaders program. This honor recognizes young researchers in the field of digestive diseases.


Looking into the Liver Transplant List

Gastroenterologist and hepatologist Julius Wilder, MD, PhD, is using funds from a recent career development award to investigate reasons why patients from underrepresented populations are less likely to be put on the liver transplant list.

Gastroenterology Leadership at the DCRI

Andrew Muir, MD, MHS, Director

Andrew Muir

Andrew J. Muir is chief of the Division of Gastroenterology and a professor of medicine at Duke University School of Medicine, as well as director of the DCRI GI Research group. Muir graduated from the Duke University School of Medicine in 1993 and completed his training in internal medicine and gastroenterology at Duke. After joining the faculty in 2000, Muir established the site-based program in clinical research for Duke GI, eventually making the transition to medical monitor and coordinating center principal investigator.